Pheno- or genotype for the CYP2C19 drug metabolism polymorphism: The influence of disease

Proceedings of the Western Pharmacology Society

Volumn 51, Issue , 2008, Pages 5-10

  Helsby, Nuala A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CLOPIDOGREL; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOKINE; DIAZEPAM; DRUG METABOLITE; HEXOBARBITAL; INDISULAM; MEPHENYTOIN; METHYLPHENOBARBITAL; NELFINAVIR; NILUTAMIDE; OMEPRAZOLE; PANTOPRAZOLE; PROGUANIL; THALIDOMIDE; VORICONAZOLE; CYP2C19 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

AGING; ANTHROPOLOGY; AUTOSOMAL RECESSIVE INHERITANCE; CAUCASIAN; CHROMOSOMAL LOCALIZATION; CONGESTIVE HEART FAILURE; CORRELATION COEFFICIENT; DOWN REGULATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME SUBSTRATE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KENYA; NEOPLASM; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROPHYLAXIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; STOP CODON; TREATMENT FAILURE; DRUG DETOXIFICATION; ETHNIC GROUP; GENE EXPRESSION REGULATION; GENERAL ASPECTS OF DISEASE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; METABOLISM; PHENOTYPE;

ARYL HYDROCARBON HYDROXYLASES; DISEASE; ETHNIC GROUPS; GENE EXPRESSION REGULATION; GENETIC VARIATION; GENOTYPE; HUMANS; METABOLIC DETOXICATION, DRUG; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 68249152634     PISSN: 00838969     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Kupfer A, Dick B, Presig R. (1982) Naunyn-Scmeideberg's Archives of Pharmacology 321, R33.
2. Klotz U. (2006). Int J Clin Pharmacol Ther 44, 297-302.
3. Coller J, Somogyi A, Bochner F. (1997) Brit J Clin Pharmacol 43, 659-660
4. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. (1991). Brit J Clin Pharmacol 31, 689-692
5. Fukasawa T, Suzuki A, Otani K. (2007) J Clin Pharm Ther 32, 333-341
6. Kim K, Park P, Hong S, Park J-Y. (2008) Clin Pharmacol Ther 84, 236-242.
7. Hirt D, Mentre F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Treluyer J-M. (2008) Brit J Clin Pharmacol 65, 548-557
8. Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H. (2007) Bioch Pharmacol 73, 2020-2026
9. Timm R, Kaiser R, Lötsch J, Heider U, Sezer O, Weisz K, Montemurro M, Roots I, Cascorbi I. (2005) Pharmacogenomics J. 5, 365-373
10. Singh G, Saxena N, Aggarwal A, Misra R. (2007) J Rheumatol 34, 731-733
11. Uttamsingh V, Lu C, Miwa G, Gan L-S. (2005) Drug Metab Dispos 33, 1723-1728
12. Li Y, Hou J, Jiang H, Wang D, Fu W, Yuan Z, Chen Y, Zhou L.(2007) Haematologica 92, 1246-1249
13. Zandvliet AS, Huitema ADR, Copalu W, Yamada Y, Tamura T, Beijnen JH, Schellens JHM. (2007) Clin Cancer Res 13, 2970-2976
14. Horsmans Y, Lannes D, Larrey D, Tinel M, Letteron P, Loeper J, Pessayre D. (1991). Xenobiotica 21, 1559-1570
15. Ward SA, Goto F, Nakamura K, Jacqz E, Wilkinson GR, Branch RA. (1987) Clin Pharmacol Ther 42, 96-99
16. Kupfer A, Desmond P, Schenker S, Branch RA. (1979). Pharmacologist 21,
17. Kupfer A, Preisig R. (1984) Eur J Clin Pharmacol 26, 753-759
18. Helsby NA, Ward SA, Howells RE, Breckenridge AM. (1990) Brit J Clin Pharmacol 30, 287-291
19. Wright JD, Helsby NA, Ward SA. (1995) Brit J Clin Pharmacol 39, 441-444
20. Hall SD, Guengerich FP, Branch RA, Wilkinson GR. (1987) J Pharmacol Exp Ther 240, 216-222
21. Knodell RG, Dubey RK, Wilkinson GR, Guengerich FP. (1988) J Pharmacol Exp Ther 245: 845-849
22. Kupfer A, Branch RA.(1985) Clin Pharmacol Ther 38, 414-418
23. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. (1984) Clin Pharmacol Ther 36, 773-780
24. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM. (1990) Brit J Clin Pharmacol 30, 593-598
25. Watkins W, Mberu E, Nevill C, Ward S, Breckenridge A, Koech D.(1990) Trans R Soc Trop Med Hyg 84, 492-495
26. Mberu EK, Wansor T, Sato H, Nishikawa Y, Watkins WM. (1995). Trans Royal Soc Trop Med Hyg 89, 658-659
27. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. (1993) Arch Biochem Biophys 306, 240-245
28. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. (1994) J Biol Chem 269, 15419-15422
29. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. (1994) Mol Pharmacol 46, 594-598
30. Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. (1995) Genomics 28, 328-332
31. Sim SC, Risinger C, Dahl M-L, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. (2006). Clin Pharmacol Ther 79, 103-113
32. Goldstein JA, Blaisdell J. (1996) Methods Enzymol 272, 210-218
33. Masimirembwa CM, Bertilsson L, Johansson I. (1995) Clin Pharmacol Ther 57, 656-661
34. Hoskins JM, Shenfield GM, Gross AS. (1998) Brit J Clin Pharmacol 46, 499-504.
35. Chang M, Tybring G, Dahl M, Gotharson E, Saga M, Seensalu R, Bertilsson L. (1995) Br J Clin Pharmacol 39, 511-518
36. Kosuge K, Jun Y, Watanabe H, Kimura M, Nishimoto M, Ishizaki T, Ohashi K. (2001) Drug Metab Dispos 29, 1284-1289
37. Desta Z, Zhao X-J, Shin J-G, Flockhart DA.(2002) Clin Pharmacokin 41, 913-958
38. Kortunay S, Basci N, Bozkurt A, Isimer A, Sayal A, Kayaalp S. (1997) Eur J Clin Pharmacol 53, 261-264
39. Xie H-G, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. (1999) Pharmacogenetics 9, 539-549
40. Inaba T, Jorge LF, (1988) Brit J Clin Pharmacol 25, 75-79.
41. Yusuf I, Djojosubroto MW, Ikawati R, Lum K, Kaneko A, Marzuki S. (2003) Advances in Experimental Medicine & Biology 531, 37-46.
42. Kaneko A, Kaneko O, Taleo G, Bjorkman A, Kobayakawa T. (1997) Lancet 349, 921-922
43. Kaneko A, Lum J, Yaviong L, Takahashi N, Ishizaki T, Bertilsson L, Kobayakawa T, Bjorkman A. (1999). Pharmacogenetics 9, 581-590
44. Green RC. (2003) Proceedings of the international conference for the 50th anniversary of the first Lapita excavation, Kone, Noumea 2002. Eds S and C p396.
45. Masta A, Lum JK, Tsukahara T, Hwaihwanje I, Kaneko A, Paniu MM, Sapuri M, Takahashi N, Ishizaki T, Kobayakawa T, Hombhanje FW. (2003) Pharmacogenetics 13, 697-700.
46. Hsu H-L, Woad KJ, Woodfield DG, Helsby NA. (2008). Human Genomics 3, 1-6.
47. Yamada S, Onda M, Kato S, Matsuda N, Matsuhisa T, Yamada N, Miki M, Matsukura N. (2001). J Gastroenterol 36, 669-672
48. Wanwimolruk S, Pratt E, Denton J, Chalcroft S, Barron P, Broughton J. (1995) Pharmacogenetics 5, 193-198
49. Wanwimolruk S, Bhawan S, Coville P, Chalcroft S. (1998) Eur J Clin Pharmacol 54, 431-435
50. Goldstein JA. (2001) Brit J Clin Pharmacol 52, 349-355
51. McGready R SK, Seaton E, Cho T, Cho D, Ginsberg A, Edstein MD, Ashley E, Looareesuwan S, White NJ, Nosten F. (2003) Eur J Clin Pharmacol 59, 553-557
52. Palovaara S, Tybring G, Laine K. (2003). Brit J Clin Pharmacol 56, 232-237
53. Rodrigues AD, Lu P. (2004) Drug Metab Dispos 32, 364-365
54. Jurima M, Inaba T, Kalow W. (1985). Drug Metab Dispos 13: 746-749
55. Laine K, Yasar U, Widen J, Tybring G. (2003). Pharmacol Toxicol 93, 77-81.
56. Hooper W, Qing M. (1990) Clin Pharmacol Ther 48, 633-640
57. Tanaka E. (1999) J Clin Pharmacy Ther 24, 339-346
58. Tamminga WJ, Wemer J, Oosterhuis B, Wieling J, Wilffert B, de Leij LFM, de Zeeuw RA, Jonkman JHG. (1999) Eur J Clin Pharmacol 55, 177-184
59. Bebia Z, Buch S, Wilson J, Frye R, Romkes M, Cecchetti A, Chaves-Gnecco D, Branch R. (2004) Clin Pharmacol Ther 76, 618-627
60. Laine K, Tybring G, Bertilsson L. (2000). Clin Pharmacol Ther 68, 151-159
61. Yamazaki H, Shimada T. (1997) Arch Biochem Biophys 346, 161-169
62. Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T. (2005) Clin Pharmacokin 44, 1179-1189
63. Williams ML, Bhargava P, Cherrouk I, Marshall JL, Flockhart DA, Wainer IW. A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. (2000) Brit J Clin Pharmacol 49, 485-488
64. Helsby NA, Lo WY, Murray M, Findlay MPN. (2007) Proceedings of 41st Annual scientific meeting of the Australasian Society of Clinical and Experimental Pharmacologists. Adelaide, Australia, 2-6 Dec, 128.
65. Frye RF, Schneider VM, Frye CS, Feldman AM. (2002) J Cardiac Failure 8, 315-319
66. Aitken AE, Morgan ET. (2007) Drug Metab Dispos 35, 1687-1693
67. Chen Y, Ferguson SS, Negishi M, Goldstein JA. (2003). Mol Pharmacol 64, 316-324
68. Pascussi J-M, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre J-M, Maurel P, Vilarem M-J. (2000). Biochem Biophys Res Comm 274, 707-713
69. Goldstein JA, Ishizaki T, Chiba K, de Morais SMF, Bell D, Krahn PM, Evans DAP. (1997) Pharmacogenetics 7, 59-64.
70. Ribeiro V, Cavaco I. (2006). Current Drug Targets 7, 1709-1719
71. Roh H-K, Dahl M, Tybring G, Yamada H, Cha Y-N, Bertilsson L. (1996). Pharmacogenetics 6, 547-551
72. Shu Y, Zhou H-H. (2000). Acta Pharmacologica Sinica 21, 193-199